ALK Abello presents positive results for Grazax pollen vaccine |
|
|
|
Published
:
Tue, 27 Feb 2007 09:18
|
COPENHAGEN (AFX) - Danish pharmaceutical group ALK Abello AS said its tablet-based grass pollen vaccine Grazax showed very positive results for the second treatment year in the ongoing GRAZAX GT-08 study.In the second treatment year, Grazax reduces hay fever symptoms by 44 pct and reduces the need for symptom-relieving medication by 73 pct compared with placebo, ALK Abello said.ALK Abello said it has recently entered strategic alliances for the Grazax programme with the Menarini Group for some European markets and with Schering-Plough for North America.gustav.sandstrom@thomson.comgs/ambCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
Danish shares AFX at a glance outlook 